Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Sold by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC reduced its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 69.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 122,424 shares of the company's stock after selling 277,042 shares during the period. Jasper Therapeutics accounts for about 2.2% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 19th largest position. Ally Bridge Group NY LLC owned about 0.82% of Jasper Therapeutics worth $2,617,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the company. Wells Fargo & Company MN increased its stake in Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock valued at $159,000 after purchasing an additional 3,828 shares during the last quarter. EntryPoint Capital LLC acquired a new position in Jasper Therapeutics during the fourth quarter worth approximately $223,000. Jane Street Group LLC purchased a new position in Jasper Therapeutics during the third quarter worth approximately $251,000. Barclays PLC boosted its holdings in shares of Jasper Therapeutics by 320.7% in the 3rd quarter. Barclays PLC now owns 16,146 shares of the company's stock valued at $304,000 after purchasing an additional 12,308 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Jasper Therapeutics by 239.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company's stock valued at $308,000 after buying an additional 11,567 shares during the period. Hedge funds and other institutional investors own 79.85% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Royal Bank of Canada dropped their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research report on Thursday, January 9th. Finally, UBS Group assumed coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $38.00 price target on the stock. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $62.50.

Jasper Therapeutics Stock Down 5.0 %

Shares of Jasper Therapeutics stock traded down $0.24 during trading hours on Wednesday, hitting $4.50. 114,110 shares of the company's stock traded hands, compared to its average volume of 287,472. Jasper Therapeutics, Inc. has a twelve month low of $3.13 and a twelve month high of $26.84. The company has a market cap of $67.64 million, a PE ratio of -0.96 and a beta of 2.74. The stock has a 50 day simple moving average of $4.74 and a 200-day simple moving average of $11.82.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.35). As a group, equities research analysts predict that Jasper Therapeutics, Inc. will post -4.47 EPS for the current year.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.